Objective To construct a nomogram model for predicting the 3-year tumor-specific mortality risk of patients with stage II-III gastric cancer after radical resection based on nutritional inflammation metabolism-related indicators, and to explore its potential clinical value, in order to provide evidence-based basis for individualized prognosis assessment and management of gastric cancer patients. Method A total of 363 patients with stage II-III gastric cancer who underwent radical resection at Beijing Friendship Hospital, Capital Medical University from January 2018 to December 2022 were retrospectively selected as the research subjects. They were randomly divided into a training set (254 cases) and a validation set (109 cases) at a ratio of 7:3. The training set was divided into a death group (91 cases) and a survival group (163 cases) based on the prognosis outcome. Clinical baseline data and nutritional, inflammatory, and metabolic-related laboratory indicators of the patients were collected. Cox proportional hazards regression analysis was used to screen the independent influencing factors of tumor-specific death in gastric cancer patients. Based on the screening results, a prognostic nomogram model was constructed. The discrimination, goodness-of-fit, and clinical application value of the model were verified through consistency index (C-index), time-dependent ROC curve, Gronnesby-Borgan test, Bootstrap self-repeated sampling, and decision curve analysis (DCA). Result Cox proportional hazards regression analysis showed that Eastern Cooperative Oncology Group performance status (ECOG-PS)of 2-3 (HR=2.074, 95%CI=1.351-3.186,P=0.001), neutrophil-to-lymphocyte ratio (NLR)≥2.66 (HR=1.753,95%CI=1.132-2.714,P=0.012), platelet-to-lymphocyte ratio (PLR) ≥ 151.72 (HR=2.258,95%CI=1.456-3.502,P<0.001), albumin-bilirubin (ALBI) grade 2 (HR=2.057, 95%CI=1.342-3.152,P=0.001), and prognostic immune-inflammation-nutrition index (PIIN) ≥ 31.49 (HR=2.120, 95%CI=1.366-3.291, P=0.001) were independent risk factors for tumor-specific death in gastric cancer patients; albumin/globulin ratio (AGR) ≥ 1.46 (HR=0.415,95%CI=0.263-0.654,P<0.001), and prognostic nutrition index (PNI) ≥ 45 (HR=0.571, 95%CI=0.357-0.912, P=0.019) were independent protective factors for tumor-specific death in gastric cancer patients. The C-index of the prognostic nomogram model based on the above indicators for predicting tumor-specific death in gastric cancer patients was 0.850 (95%CI=0.799-0.901); the AUC of 1-year, 2-year, and 3-year survival in the training set was 0.729, 0.783, and 0.829, respectively, and in the validation set were 0.590, 0.839, and 0.829; the Gronnesby-Borgan test showed that the fitting goodness of the training set (χ2=8.762,P=0.271) and the validation set (χ2=9.125,P=0.244) was good; the internal validation and decision curve of the Bootstrap method showed that the net benefit interval of the model for predicting tumor-specific death in gastric cancer patients was large, which was helpful for clinical decision-making. Conclusion The prognostic nomogram model constructed based on multiple-dimensional indicators of nutrition, inflammation, and metabolism in gastric cancer patients has good predictive efficacy and clinical practicability, can stratify the prognosis risk of gastric cancer patients, and provides scientific basis for the formulation of individualized intervention strategies such as perioperative nutritional support, anti-inflammation, and metabolic regulation for gastric cancer patients.
Key words
Gastric cancer /
Radical resection /
Nutritional status /
Inflammatory response /
Tumor metabolism /
Prognosis /
Nomogram /
Risk factors
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Park J Y, Georges D, Alberts C J, et al. Global lifetime estimates of expected and preventable gastric cancers across 185 countries[J]. Nat Med, 2025,31(9):3020-3027.
[2] Lin J L, Lin J X, Lin G T, et al. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035[J]. BMC Public Health, 2024,24(1):1763.
[3] Wu M, Liu N, Li S, et al. Identification of prognostic indicators for early recurrence of gastric cancer following laparoscopic gastrectomy[J]. BMC Surg, 2025,25(1):541.
[4] Kang M K, Lee H J. Impact of malnutrition and nutritional support after gastrectomy in patients with gastric cancer[J]. Ann Gastroenterol Surg, 2024,8(4):534-552.
[5] Wei J, Xiang W, Wei H, et al. Impact of nutrition risk index, prognostic nutritional index and skeletal muscle index on early myelosuppression of first-line chemotherapy in stage IV gastric cancer patients[J]. BMC Gastroenterol, 2024,24(1):452.
[6] Bakrim S, Fessikh M E, Elhrech H, et al. Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches[J]. J Transl Med, 2025,23(1):588.
[7] Liu J, Sun R, Cai K, et al. A nomogram combining neutrophil to lymphocyte ratio (NLR) and prognostic nutritional index (PNI) to predict distant metastasis in gastric cancer[J]. Sci Rep, 2024,14(1):15391.
[8] Zeng Q, Wang S, Bai Z, et al. Platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with gastric cancer undergoing radical resection. Front Oncol[J]. 2024,14(3):1279011.
[9] Cortellino S, D'angelo M, Quintiliani M, et al. Cancer knocks you out by fasting: Cachexia as a consequence of metabolic alterations in cancer[J]. J Cell Physiol, 2025,240(1):e31417.
[10] 谢凯强,冯绾,刘竹贤,等. 术前L3-SMI、AGR、PNI对胃癌根治术后患者总体生存的预测价值[J]. 中南大学学报(医学版),2025,50(2):204-214.
[11] 王永光,王悦,韩道正,等. 胃癌根治术后患者临床预后影响因素及与术前ALBI分级的相关性研究[J]. 罕少疾病杂志,2023,30(5):77-78.
[12] 罗鑫婷,王红兵,掌辕轩,等. 基于预后免疫-炎症-营养评分胃癌根治术患者预后预测模型的构建[J]. 医学研究杂志,2025,54(7):152-157,84.
[13] Qin Y, Liu Y, Dong P, et al. The heterogeneous roles of neutrophils in gastric cancer: scaffold or target[J]. Cell Mol Biol Lett, 2025,30(1):71.
[14] Wang Y, Li X, Huang J, et al. Factors influencing pathological response after neoadjuvant therapy for advanced gastric cancer[J]. Am J Transl Res, 2025,17(4):2907-2915.
[15] Zhong Q, Weng C M, Jiang M C, et al. Patterns of Survival and Recurrence in Poor Responders to Neoadjuvant Therapy for Gastric Cancer: A Real-World Multicenter Study[J]. Ann Surg Oncol, 2025,32(9):6794-6804.
[16] Aoyama T, Maezawa Y, Hashimoto I, et al. Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment[J]. Anticancer Res, 2023,43(9):3849-3860.
[17] 罗俊峰,胡军,李包根,等. 基于炎症反应评分系统构建胃癌患者预后的列线图预测模型[J]. 中国肿瘤生物治疗杂志,2023,30(10):902-907.
[18] Zhu M, Zhang LT, Lai W, et al. Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study[J]. Peer J, 2024,12(12):e18659.
[19] Yang S, Li Z, Wang T, et al. Correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with prognosis in gastric cancer patients undergoing neoadjuvant chemotherapy: a meta-analysis[J]. BMC Gastroenterol, 2025,25(1):445.
[20] Li L L, Pan L S. Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: A meta-analysis[J]. Kaohsiung J Med Sci, 2023,39(8):842-852.
[21] Kim J, Choi H, Jeun S S, et al. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma[J]. Cancer Lett, 2024,588(4):216714.
[22] Mirestean C C, Iancu R I, Iancu D T. Immunotherapy and radiotherapy - a future partnership Focus on radiation induced lymphopenia (RIL) implications[J]. Bratisl Lek Listy, 2023,124(1):70-73.
[23] Liu S, Liu J, Cheng X, et al. Application value of platelet-to-lymphocyte ratio as a novel indicator in rheumatoid arthritis: a review based on clinical evidence[J]. J Inflamm Res, 2024,17(10):7607-7617.
[24] Cai C, Liu Y, Lu R, et al. Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities[J]. Exp Hematol Oncol, 2025,14(1):83.
[25] Gan J, Zhang X, Guo J. The role of platelets in tumor immune evasion and metastasis: mechanisms and therapeutic implications[J]. Cancer Cell Int, 2025,25(1):258.
[26] Li Y, Chen L, Yang X, et al. Dynamic association of serum albumin changes with inflammation, nutritional status and clinical outcomes: a secondary analysis of a large prospective observational cohort study[J]. Eur J Med Res, 2025,30(1):679.
[27] Ward E S, Gelinas D, Dreesen E, et al. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders[J]. Front Immunol, 2022,13(1):892534.
[28] Nara K, Yamamoto T, Yamashita H, et al. Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study[J]. BMC Cancer, 2023,23(1):979.
[29] Shoka M, Kanda M, Ito S, et al. Modified Albumin-Bilirubin Grade optimized for risk stratification of patients with stage II-Ⅲ gastric cancer[J]. Surg Today, 2023,53(10):1149-1159.
[30] Punzo A, Silla A, Fogacci F, et al. Bile Acids and Bilirubin Role in Oxidative Stress and Inflammation in Cardiovascular Diseases[J]. Diseases, 2024,12(5):103.
[31] Wang L, Chen M Z, Liu L, et al. Novel inflammatory-nutritional prognostic index for advanced gastric cancer patients undergoing gastrectomy and prophylactic hyperthermic intraperitoneal chemotherapy[J]. World J Gastrointest Surg, 2025,17(5):102201.
[32] 刘茜,蒋超,冯婉婷. 白蛋白/球蛋白与预后营养指数在胃癌患者中的预后意义及预测模型的建立[J]. 皖南医学院学报,2025,44(1):94-98.
[33] Seluk Y,Mehmet K,Cihan T D, et al.Predictive value of systemic immune inflammation index (SII) and prognostic nutritional index (PNI) on mortality after below-knee amputation[J].Medicine,2023,102(43):e35703.
[34] 牛林军,李心忠,闾永健. 基于Ki67构建晚期胃癌预后的预测模型[J]. 中国临床研究,2025,38(7):1038-1042.
[35] Zhao Z, Dai E, Jin B, et al. A prognostic nomogram to predict the cancer-specific survival of patients with initially diagnosed metastatic gastric cancer: a validation study in a Chinese cohort[J]. Clin Transl Oncol, 2025,27(1):135-150.
[36] Diao P, Wang Y, Wang X, et al. Immune mediation between sarcopenia, performance status, and survival in gastric cancer patients undergoing radical resection[J]. Front Oncol, 2025,15(12):1670034.
[37] 吴亮亮,蔡明志,王宝贵,等. 术前炎性反应和营养指标对胃癌预后的预测价值及其模型构建[J]. 中华胃肠外科杂志,2023,26(7):680-688.
[38] Li R, Liu Q, Wang H, et al. Nomogram based on the novel index LANR, composed of preoperative lymphocytes, albumin, and neutrophils, for predicting prognosis in patients with gastric cancer: a retrospective study[J]. Front Oncol, 2025,15(9):1634948.
[39] Wang Z, Li J, Zhang Q, et al. Comparative effectiveness of different prehabilitation strategies in patients undergoing digestive system cancer surgery: a network meta-analysis[J]. J Gastrointest Surg, 2025,29(8):102119.
[40] 刘铄,陈萌,路洪超,等. 塞来昔布联合化疗对转移性或术后复发性晚期胃癌的疗效及药物不良反应[J]. 肿瘤药学,2022,12(5):626-631.
PDF(4826 KB)
